bioRxiv : the preprint server for biology · 2026
Characterization of the knock-in App SAA mouse model as a powerful tool for Alzheimer's disease preclinical research.
СтатьяПрепринтНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sloan Lucy J, Garceau Dylan T, Ryan Nick J, Pomeroy-Tuck Justice, Chidambaram Ritesh, Ragan Tim, Pandey Ravi S, Bloss Erik B, Carter Gregory W, Oblak Adrian L, Sasner Michael
Аннотация
BACKGROUND: Preclinical Alzheimer's disease (AD) research requires models with age-dependent, physiologically relevant amyloid pathology, unlike overexpression in transgenic lines. We characterized the humanized App SAA knock-in model to define translationally relevant therapeutic windows.
METHODS: Homozygous App SAA and control mice were evaluated from 4 to 19 months using whole-brain 3D plaque imaging, cerebral amyloid angiopathy (CAA) quantification, multiplex neuropathology, brain transcriptomics, and plasma biomarkers. Hippocampal synaptic analysis and context-dependent memory was performed at 12 months.
RESULTS: Plaques, CAA, plaque-associated neuroinflammation, and dystrophic neurites accumulated with age. By 12 months, brain transcriptomes aligned with human AMP-AD co-expression modules, and plasma pTau-217, GFAP, and SNAP25 rose with age. App SAA mice retained associative memory but showed memory interference and CA1 dendritic-spine loss that was exacerbated in proximity to plaques.
CONCLUSIONS: App SAA mice recapitulate age-dependent, human-relevant AD phenotypes with defined therapeutic windows for preclinical research. The model is available without restriction from The Jackson Laboratory.
METHODS: Homozygous App SAA and control mice were evaluated from 4 to 19 months using whole-brain 3D plaque imaging, cerebral amyloid angiopathy (CAA) quantification, multiplex neuropathology, brain transcriptomics, and plasma biomarkers. Hippocampal synaptic analysis and context-dependent memory was performed at 12 months.
RESULTS: Plaques, CAA, plaque-associated neuroinflammation, and dystrophic neurites accumulated with age. By 12 months, brain transcriptomes aligned with human AMP-AD co-expression modules, and plasma pTau-217, GFAP, and SNAP25 rose with age. App SAA mice retained associative memory but showed memory interference and CA1 dendritic-spine loss that was exacerbated in proximity to plaques.
CONCLUSIONS: App SAA mice recapitulate age-dependent, human-relevant AD phenotypes with defined therapeutic windows for preclinical research. The model is available without restriction from The Jackson Laboratory.